Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review

Kokuvi Atsou, Christos Chouaid, Gilles Hejblum, Kokuvi Atsou, Christos Chouaid, Gilles Hejblum

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is predicted to become a major cause of death worldwide. Studies on the variability in the estimates of key epidemiological parameters of COPD may contribute to better assessment of the burden of this disease and to helpful guidance for future research and public policies. In the present study, we examined differences in the main epidemiological characteristics of COPD derived from studies across countries of the European Union, focusing on prevalence, severity, frequency of exacerbations and mortality, as well as on differences between the studies' methods.

Methods: This systematic review was based on a search for the relevant literature in the Science Citation Index database via the Web of Science and on COPD mortality rates issued from national statistics. Analysis was finally based on 65 articles and Eurostat COPD mortality data for 21 European countries.

Results: Epidemiological characteristics of COPD varied widely from country to country. For example, prevalence estimates ranged between 2.1% and 26.1%, depending on the country, the age group and the methods used. Likewise, COPD mortality rates ranged from 7.2 to 36.1 per 10(5) inhabitants. The methods used to estimate these epidemiological parameters were highly variable in terms of the definition of COPD, severity scales, methods of investigation and target populations. Nevertheless, to a large extent, several recent international guidelines or research initiatives, such as GOLD, BOLD or PLATINO, have boosted a substantial standardization of methodology in data collection and have resulted in the availability of more comparable epidemiological estimates across countries. On the basis of such standardization, severity estimates as well as prevalence estimates present much less variation across countries. The contribution of these recent guidelines and initiatives is outlined, as are the problems remaining in arriving at more accurate COPD epidemiological estimates across European countries.

Conclusions: The accuracy of COPD epidemiological parameters is important for guiding decision making with regard to preventive measures, interventions and patient management in various health care systems. Therefore, the recent initiatives for standardizing data collection should be enhanced to result in COPD epidemiological estimates of improved quality. Moreover, establishing international guidelines for reporting research on COPD may also constitute a major contribution.

Figures

Figure 1
Figure 1
Flowchart of the process for collecting information included in the review.
Figure 2
Figure 2
The most popular chronic obstructive pulmonary disease classifications: ERS, European Respiratory Society; ATS, American Thoracic Society; SPLF, Société de Pneumologie de Langue Française; BTS, British Thoracic Society; GOLD, Global Initiative for Chronic Obstructive Lung Disease; FEV1, forced expiratory volume in 1 second. ATS, BTS, ERS and SPLF classifications define three stages of severity between 0% and 100% (ATS and ERS) or 80% (BTS and SPLF) of predicted FEV1. The most recent classification is the GOLD classification, which was initially proposed in 2001 and has been modified twice, in 2003 and 2006. In 2003, the GOLD classification evolved from three to four stages plus a supplementary stage 0 defining patients at risk (that is, the presence of chronic cough and sputum, but no obstruction together with FEV1 over forced vital capacity ratio >70%; stage 0 is not shown in the figure), and stage 0 was not kept in the GOLD classification system in 2006.

References

    1. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932–946. doi: 10.1183/09031936.04.00014304.
    1. Hurd S, Pauwels R. Global Initiative for Chronic Obstructive Lung Diseases (GOLD) Pulm Pharmacol Ther. 2002;15:353–355. doi: 10.1006/pupt.2002.0381.
    1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442. doi: 10.1371/journal.pmed.0030442.
    1. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA. 2005;294:1255–1259. doi: 10.1001/jama.294.10.1255.
    1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349:1498–1504. doi: 10.1016/S0140-6736(96)07492-2.
    1. Bellamy D, Bouchard J, Henrichsen S, Johansson G, Langhammer A, Reid J, van Weel C, Buist S. International Primary Care Respiratory Group (IPCRG) Guidelines: management of chronic obstructive pulmonary disease (COPD) Prim Care Respir J. 2006;15:48–57. doi: 10.1016/j.pcrj.2005.11.003.
    1. Société de Pneumologie de Langue Française. [Recommendations of the Francophone Society of Pneumology for pulmonary rehabilitation in COPD] [Article in French] Rev Mal Respir. 2005;22:696–704.
    1. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007;370:741–750. doi: 10.1016/S0140-6736(07)61377-4.
    1. Menezes AM, Perez-Padilla R, Jardim JR, Muiño A, Lopez MV, Valdivia G, Montes de Oca M, Talamo C, Hallal PC, Victora CG. PLATINO team. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet. 2005;366:1875–1881. doi: 10.1016/S0140-6736(05)67632-5.
    1. Eurostat. Causes of death: Standardised death rate (per 100,000 inhabitants) (Annual Data)
    1. Jaén A, Ferrer A, Ormaza I, Rué M, Domingo C, Marín A. [Prevalence of chronic bronchitis, asthma and airflow limitation in an urban-industrial area of Catalonia] [Article in Spanish] Arch Bronconeumol. 1999;35:122–128.
    1. Marco Jordán L, Martín Berra JC, Corres Iñigo M, Luque Díez R, Zubillaga Garmendia G. [Chronic obstructive lung disease in the general population. An epidemiologic study performed in Guipúzcoa] [Article in Spanish] Arch Bronconeumol. 1998;34:23–27.
    1. Brotons B, Pérez JA, Sánchez-Toril F, Soriano S, Hernández J, Belenguer JL. [The prevalence of chronic obstructive pulmonary disease and asthma: a cross-sectional study] [Article in Spanish] Arch Bronconeumol. 1994;30:149–152.
    1. Piperno D, Bart F, Serrier P, Zureik M, Finkielsztejn L. [General practice patients at risk of chronic obstructive pulmonary disease: epidemiologic survey of 3,411 patients] [Article in French] Presse Med. 2005;34:1617–1622. doi: 10.1016/S0755-4982(05)84236-8.
    1. Cerveri I, Accordini S, Corsico A, Zoia MC, Carrozzi L, Cazzoletti L, Beccaria M, Marinoni A, Viegi G, de Marco R. Chronic cough and phlegm in young adults. Eur Respir J. 2003;22:413–417. doi: 10.1183/09031936.03.00121103.
    1. Huchon GJ, Vergnenegre A, Neukirch F, Brami G, Roche N, Preux PM. Chronic bronchitis among French adults: high prevalence and underdiagnosis. Eur Respir J. 2002;20:806–812. doi: 10.1183/09031936.02.00042002.
    1. Cerveri I, Accordini S, Verlato G, Corsico A, Zoia MC, Casali L, Burney P, de Marco R. Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adults. Eur Respir J. 2001;18:85–92. doi: 10.1183/09031936.01.00087101.
    1. Cazzola M, Bettoncelli G, Sessa E, Cricelli C. Primary care of the patient with chronic obstructive pulmonary disease in Italy. Respir Med. 2009;103:582–588. doi: 10.1016/j.rmed.2008.10.017.
    1. Schirnhofer L, Lamprecht B, Vollmer WM, Allison MJ, Studnicka M, Jensen RL, Buist AS. COPD prevalence in Salzburg, Austria: results from the Burden of Obstructive Lung Disease (BOLD) Study. Chest. 2007;131:29–36. doi: 10.1378/chest.06-0365.
    1. Montnemery R, Nihlen U, Andersson M, Greiff L, Johannisson A, Nyberg P, Persson CG, Lofdahl CG. Obstructive airways diseases, smoking and use of inhaled corticosteroids in southern Sweden in 1992 and 2000. Int J Tuberc Lung Dis. 2006;10:490–498.
    1. Hedman J, Kaprio J, Poussa T, Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol. 1999;28:717–722. doi: 10.1093/ije/28.4.717.
    1. Montnemery P, Adelroth E, Heuman K, Johannisson A, Johansson SA, Lindholm LH, Lundback B, Lofdahl CG. Prevalence of obstructive lung diseases and respiratory symptoms in southern Sweden. Respir Med. 1998;92:1337–1345. doi: 10.1016/S0954-6111(98)90139-1.
    1. Lundback B, Nystrom L, Rosenhall L, Stjernberg N. Obstructive lung disease in northern Sweden: respiratory symptoms assessed in a postal survey. Eur Respir J. 1991;4:257–266.
    1. Miravitlles M, Soriano JB, Garcia-Rio F, Munoz L, Duran-Tauleria E, Sanchez G, Sobradillo V, Ancochea J. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax. 2009;64:863–868. doi: 10.1136/thx.2009.115725.
    1. Van Durme YM, Verhamme KM, Stijnen T, van Rooij FJ, Van Pottelberge GR, Hofman A, Joos GF, Stricker BH, Brusselle GG. Prevalence, incidence, and lifetime risk for the development of COPD in the elderly: the Rotterdam study. Chest. 2009;135:368–377. doi: 10.1378/chest.08-0684.
    1. Hansen JG, Pedersen L, Overvad K, Omland Ø, Jensen HK, Sørensen HT. The prevalence of chronic obstructive pulmonary disease among Danes aged 45-84 years: population-based study. COPD. 2008;5:347–352. doi: 10.1080/15412550802522635.
    1. Bednarek M, Maciejewski J, Wozniak M, Kuca P, Zielinski J. Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax. 2008;63:402–407. doi: 10.1136/thx.2007.085456.
    1. Roche N, Dalmay F, Perez T, Kuntz C, Vergnenegre A, Neukirch F, Giordanella JP, Huchon G. Impact of chronic airflow obstruction in a working population. Eur Respir J. 2008;31:1227–1233. doi: 10.1183/09031936.00089607.
    1. Shahab L, Jarvis MJ, Britton J, West R. Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. Thorax. 2006;61:1043–1047. doi: 10.1136/thx.2006.064410.
    1. Stavem K, Sandvik L, Erikssen J. Can Global Initiative for Chronic Obstructive Lung Disease stage 0 provide prognostic information on long-term mortality in men? Chest. 2006;130:318–325. doi: 10.1378/chest.130.2.318.
    1. Sichletidis L, Tsiotsios I, Gavriilidis A, Chloros D, Kottakis I, Daskalopoulou E, Konstantinidis T. Prevalence of chronic obstructive pulmonary disease and rhinitis in northern Greece. Respiration. 2005;72:270–277. doi: 10.1159/000085368.
    1. Murtagh E, Heaney L, Gingles J, Shepherd R, Kee F, Patterson C, MacMahon J. Prevalence of obstructive lung disease in a general population sample: the NICECOPD study. Eur J Epidemiol. 2005;20:443–453. doi: 10.1007/s10654-005-1248-8.
    1. Tzanakis N, Anagnostopoulou U, Filaditaki V, Christaki P, Siafakas N. Prevalence of COPD in Greece. Chest. 2004;125:892–900. doi: 10.1378/chest.125.3.892.
    1. Hasselgren M, Arne M, Lindahl A, Janson S, Lundback B. Estimated prevalences of respiratory symptoms, asthma and chronic obstructive pulmonary disease related to detection rate in primary health care. Scand J Prim Health Care. 2001;19:54–57. doi: 10.1080/028134301300034701.
    1. Peña VS, Miravitlles M, Gabriel R, Jiménez-Ruiz CA, Villasante C, Masa JF, Viejo JL, Fernández-Fau L. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest. 2000;118:981–989.
    1. Viegi G, Pedreschi M, Pistelli F, Di Pede F, Baldacci S, Carrozzi L, Giuntini C. Prevalence of airways obstruction in a general population: European Respiratory Society vs American Thoracic Society definition. Chest. 2000;117(Suppl 2):339–345. doi: 10.1378/chest.117.5_suppl_2.339S.
    1. Dickinson JA, Meaker M, Searle M, Ratcliffe G. Screening older patients for obstructive airways disease in a semi-rural practice. Thorax. 1999;54:501–505. doi: 10.1136/thx.54.6.501.
    1. Renwick DS, Connolly MJ. Prevalence and treatment of chronic airways obstruction in adults over the age of 45. Thorax. 1996;51:164–168. doi: 10.1136/thx.51.2.164.
    1. Bakke PS, Baste V, Hanoa R, Gulsvik A. Prevalence of obstructive lung disease in a general population: relation to occupational title and exposure to some airborne agents. Thorax. 1991;46:863–870. doi: 10.1136/thx.46.12.863.
    1. Peabody JW, Schau B, Lopez-Vidriero M, Vestbo J, Wade S, Iqbal A. COPD: a prevalence estimation model. Respirology. 2005;10:594–602. doi: 10.1111/j.1440-1843.2005.00755.x.
    1. Feenstra TL, van Genugten ML, Hoogenveen RT, Wouters EF, Rutten-van Molken MP. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am J Respir Crit Care Med. 2001;164:590–596.
    1. Stang P, Lydick E, Silberman C, Kempel A, Keating ET. The prevalence of COPD: using smoking rates to estimate disease frequency in the general population. Chest. 2000;117(Suppl 2):354–359. doi: 10.1378/chest.117.5_suppl_2.354S.
    1. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;152:S77–S121.
    1. The COPD Guidelines Group of the Standards of Care Committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax. 1997;52(Suppl 5):1–28.
    1. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, Yernault JC, Decramer M, Higenbottam T, Postma DS, Rees J. on behalf of the European Respiratory Society Task Force. Optimal assessment and management of chronic obstructive pulmonary disease (COPD): the European Respiratory Society Task Force. Eur Respir J. 1995;8:1398–1420. doi: 10.1183/09031936.95.08081398.
    1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532–555. doi: 10.1164/rccm.200703-456SO.
    1. Lindberg A, Bjerg-Backlund A, Ronmark E, Larsson LG, Lundback B. Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking: report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med. 2006;100:264–272. doi: 10.1016/j.rmed.2005.04.029.
    1. De Marco R, Accordini S, Cerveri I, Corsico A, Sunyer J, Neukirch F, Kunzli N, Leynaert B, Janson C, Gislason T, Vermeire P, Svanes C, Anto JM, Burney P. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax. 2004;59:120–125. doi: 10.1136/thorax.2003.011163.
    1. Jansson SA, Andersson F, Borg S, Ericsson Å, Jönsson E, Lundback B. Costs of COPD in Sweden according to disease severity. Chest. 2002;122:1994–2002. doi: 10.1378/chest.122.6.1994.
    1. Von Hertzen L, Reunanen A, Impivaara O, Malkia E, Aromaa A. Airway obstruction in relation to symptoms in chronic respiratory disease: a nationally representative population study. Respir Med. 2000;94:356–363. doi: 10.1053/rmed.1999.0715.
    1. Izquierdo JL, Barcina C, Jimenez J, Munoz M, Leal M. Study of the burden on patients with chronic obstructive pulmonary disease. Int J Clin Pract. 2009;63:87–97. doi: 10.1111/j.1742-1241.2008.01936.x.
    1. Hoogendoorn M, Feenstra TL, Schermer TR, Hesselink AE, Rutten-van Molken MP. Severity distribution of chronic obstructive pulmonary disease (COPD) in Dutch general practice. Respir Med. 2006;100:83–86. doi: 10.1016/j.rmed.2005.04.004.
    1. Detournay B, Pribil C, Fournier M, Housset B, Huchon G, Huas D, Godard P, Voinet C, Chanal I, Jourdanne C, Durand-Zaleski I. The SCOPE study: health-care consumption related to patients with chronic obstructive pulmonary disease in France. Value Health. 2004;7:168–174. doi: 10.1111/j.1524-4733.2004.72329.x.
    1. Soriano JB, Maier WC, Egger P, Visick G, Thakrar B, Sykes J, Pride NB. Recent trends in physician diagnosed COPD in women and men in the UK. Thorax. 2000;55:789–794. doi: 10.1136/thorax.55.9.789.
    1. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60:925–931.
    1. Tsoumakidou M, Tzanakis N, Voulgaraki O, Mitrouska I, Chrysofakis G, Samiou M, Siafakas NM. Is there any correlation between the ATS, BTS, ERS and GOLD COPD's severity scales and the frequency of hospital admissions? Respir Med. 2004;98:178–183. doi: 10.1016/j.rmed.2003.09.011.
    1. Kornmann O, Beeh KM, Beier J, Geis UP, Ksoll M, Buhl R. Newly diagnosed chronic obstructive pulmonary disease: clinical features and distribution of the novel stages of the Global Initiative for Obstructive Lung Disease. Respiration. 2003;70:67–75. doi: 10.1159/000068417.
    1. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA. Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax. 2003;58:654–658. doi: 10.1136/thorax.58.8.654.
    1. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361:449–456. doi: 10.1016/S0140-6736(03)12459-2.
    1. Jones PW, Willits LR, Burge PS, Calverley PM. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J. 2003;21:68–73. doi: 10.1183/09031936.03.00013303.
    1. Andersson F, Borg S, Jansson SA, Jonsson AC, Ericsson A, Prutz C, Ronmark E, Lundback B. The costs of exacerbations in chronic obstructive pulmonary disease (COPD) Respir Med. 2002;96:700–708. doi: 10.1053/rmed.2002.1334.
    1. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320:1297–1303. doi: 10.1136/bmj.320.7245.1297.
    1. Effing T, Kerstjens H, van der Valk P, Zielhuis G, van der Palen J. (Cost)-effectiveness of self-treatment of exacerbations on the severity of exacerbations in patients with COPD: the COPE II study. Thorax. 2009;64:956–962. doi: 10.1136/thx.2008.112243.
    1. Worth H, Schacher C, Dethlefsen U. Concomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: a placebo-controlled double-blind trial. Respir Res. 2009;10:69. doi: 10.1186/1465-9921-10-69.
    1. Schermer T, Chavannes N, Dekhuijzen R, Wouters E, Muris J, Akkermans R, van Schayck O, van Weel C. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. Respir Med. 2009;103:542–551. doi: 10.1016/j.rmed.2008.11.003.
    1. O'Reilly JF, Williams AE, Holt K, Rice L. Defining COPD exacerbations: impact on estimation of incidence and burden in primary care. Prim Care Respir J. 2006;15:346–353.
    1. Wilkinson TM, Donaldson GC, Johnston SL, Openshaw PJ, Wedzicha JA. Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173:871–876. doi: 10.1164/rccm.200509-1489OC.
    1. Donaldson GC, Seemungal TA, Patel IS, Lloyd-Owen SJ, Wilkinson TM, Wedzicha JA. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J. 2003;22:931–936. doi: 10.1183/09031936.03.00038303.
    1. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1608–1613.
    1. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178:1139–1147. doi: 10.1164/rccm.200801-145OC.
    1. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543–1554. doi: 10.1056/NEJMoa0805800.
    1. Calverley PM, Rennard S, Nelson HS, Karpel JP, Abbate EH, Stryszak P, Staudinger H. One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respir Res. 2008;9:73. doi: 10.1186/1465-9921-9-73.
    1. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177:19–26. doi: 10.1164/rccm.200707-973OC.
    1. Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J. 2006;27:547–555. doi: 10.1183/09031936.06.00062705.
    1. Oostenbrink JB, Rutten-van Mölken MP, Al MJ, Van Noord JA, Vincken W. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J. 2004;23:241–249. doi: 10.1183/09031936.03.00083703.
    1. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003;58:399–404. doi: 10.1136/thorax.58.5.399.
    1. Borg S, Ericsson A, Wedzicha J, Gulsvik A, Lundback B, Donaldson GC, Sullivan SD. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health. 2004;7:153–167. doi: 10.1111/j.1524-4733.2004.72318.x.
    1. Hurd S. The impact of COPD on lung health worldwide: epidemiology and incidence. Chest. 2000;117(Suppl):1–4. doi: 10.1378/chest.117.2_suppl.1S.
    1. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest. 2003;124:459–467. doi: 10.1378/chest.124.2.459.
    1. Almagro P, Calbo E, Ochoa de Echaguen A, Barreiro B, Quintana S, Heredia JL, Garau J. Mortality after hospitalization for COPD. Chest. 2002;121:1441–1448. doi: 10.1378/chest.121.5.1441.
    1. Gudmundsson G, Gislason T, Lindberg E, Hallin R, Ulrik CS, Brondum E, Nieminen MM, Aine T, Bakke P, Janson C. Mortality in COPD patients discharged from hospital: the role of treatment and co-morbidity. Respir Res. 2006;7:109. doi: 10.1186/1465-9921-7-109.
    1. Arne M, Lisspers K, Stallberg B, Boman G, Hedenstrom H, Janson C, Emtner M. How often is diagnosis of COPD confirmed with spirometry? Respir Med. 2010;104:550–556. doi: 10.1016/j.rmed.2009.10.023.
    1. Jones RC, Donaldson GC, Chavannes NH, Kida K, Dickson-Spillmann M, Harding S, Wedzicha JA, Price D, Hyland ME. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med. 2009;180:1189–1195. doi: 10.1164/rccm.200902-0271OC.
    1. Puhan MA, Garcia-Aymerich J, Frey M, ter Riet G, Antó JM, Agustí AG, Gómez FP, Rodríguez-Roisín R, Moons KG, Kessels AG, Held U. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet. 2009;374:704–711. doi: 10.1016/S0140-6736(09)61301-5.
    1. Aaron SD, Fergusson D, Marks GB, Suissa S, Vandemheen KL, Doucette S, Maltais F, Bourbeau JF, Goldstein RS, Balter M, O'Donnell D, Fitzgerald M. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax. 2008;63:122–128. doi: 10.1136/thx.2007.082636.
    1. Anderson RN, Minino AM, Hoyert DL, Rosenberg HM. Comparability of cause of death between ICD-9 and ICD-10: preliminary estimates. Natl Vital Stat Rep. 2001;49:1–32.
    1. Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax. 2003;58:388–393. doi: 10.1136/thorax.58.5.388.
    1. EQUATOR Network. Library for health research reporting.
    1. Loddenkemper R, Gibson GJ, Sibille Y. European Lung White Book. Lausanne, Switzerland: ERS Ltd; 2003. The burden of lung disease in Europe.
    1. Burney P, Suissa S, Soriano JB, Vollmer WM, Viegi G, Sullivan SD, Fabbri LM, Sin DD, Ernst P, Coultas D, Bourbeau J, Mapel DW, Weiss K, McLaughlin T, Price D, Sturkenboom MC, Taylor R, Hagan GW. The pharmacoepidemiology of COPD: recent advances and methodological discussion. Eur Respir J. 2003;22(Suppl 43):41s–44s.

Source: PubMed

3
订阅